Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effectiveness of insulin delivered in the peritoneum (abdomen)by an implantable pump in Type 1 diabetics.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medtronic Diabetes
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

• Type 1 diabetes mellitus (American Diabetes Association definition)

• HbA1c greater than or equal to 7.5%

• Intensive insulin treatment for at least 3 months

• Physical and intellectual ability to operate MIP system

• Subject has been under the routine care of the investigator for at least two months prior to enrollment

• Subject has a reliable support person (defined as a person who has daily contact with the subject and knows whom to contact in the event of an emergency).

• Capability and willingness to perform self-monitoring of blood glucose at least four times daily for 9 months of the study and 7 times daily for 3 months of the study

• Physical and intellectual ability to operate the MIP system and to comply with the data reporting requirements of the study.

• Subject is willing to sign the informed consent form (approved by local Institutional Review Board and Medtronic MiniMed)

Exclusion Criteria:

• The subject's insulin usage exceeds 66 units per day.

• Severe complications such as advanced autonomic neuropathy, legal blindness, or symptomatic cardiovascular disease as evidenced by a cardiovascular episode within the last six months

• Reside at or plan to travel to elevations above 8000 feet during the study period (commercial airline travel is acceptable)

• Subject who is pregnant, of childbearing potential or lactating and is neither surgically sterile, using contraceptives (devices, oral or implanted) nor other physician approved contraceptive

• The subject has any major concomitant disease or any physical or psychological disorder within the last five years, which might be considered life threatening, or which might confound the collection or interpretation of the study data

• The subject has previously enrolled in or participated in an investigational drug or device study within the preceding 4 weeks

• The subject has any condition that precludes him/her from completing the study requirements

• Has plans for activities which require them to go 25 feet below sea level